NeuroSense Therapeutics is a drug development company offering a treatment for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

The companys drug, PrimeC, is a unique formulation combining two FDA-approved compounds for unrelated conditions.The company was granted an orphan drug designation by the FDA and the EMA for the use of PrimeC in ALS patients.

NeuroSense Therapeutics is currently running two clinical trials in patients with ALS, in Israel and the United States.